- Home
- UGRO vs GRI Comparison
UGRO vs GRI Comparison
Compare UGRO & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UGRO
- GRI
- Stock Information
- Founded
- UGRO 2014
- GRI 2018
- Country
- UGRO United States
- GRI United States
- Employees
- UGRO N/A
- GRI N/A
- Industry
- UGRO Industrial Specialties
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- UGRO Consumer Discretionary
- GRI Health Care
- Exchange
- UGRO Nasdaq
- GRI Nasdaq
- Market Cap
- UGRO 3.8M
- GRI 3.4M
- IPO Year
- UGRO N/A
- GRI N/A
- Fundamental
- Price
- UGRO $0.32
- GRI $1.65
- Analyst Decision
- UGRO Strong Buy
- GRI Strong Buy
- Analyst Count
- UGRO 1
- GRI 2
- Target Price
- UGRO $3.00
- GRI $22.00
- AVG Volume (30 Days)
- UGRO 538.3K
- GRI 136.5K
- Earning Date
- UGRO 07-22-2025
- GRI 08-13-2025
- Dividend Yield
- UGRO N/A
- GRI N/A
- EPS Growth
- UGRO N/A
- GRI N/A
- EPS
- UGRO N/A
- GRI N/A
- Revenue
- UGRO $59,985,138.00
- GRI N/A
- Revenue This Year
- UGRO N/A
- GRI N/A
- Revenue Next Year
- UGRO $31.25
- GRI N/A
- P/E Ratio
- UGRO N/A
- GRI N/A
- Revenue Growth
- UGRO N/A
- GRI N/A
- 52 Week Low
- UGRO $0.26
- GRI $1.10
- 52 Week High
- UGRO $1.92
- GRI $43.69
- Technical
- Relative Strength Index (RSI)
- UGRO 55.26
- GRI 57.27
- Support Level
- UGRO $0.29
- GRI $1.39
- Resistance Level
- UGRO $0.34
- GRI $1.45
- Average True Range (ATR)
- UGRO 0.04
- GRI 0.12
- MACD
- UGRO 0.01
- GRI 0.05
- Stochastic Oscillator
- UGRO 49.04
- GRI 69.79
About UGRO urban-gro Inc.
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.